1. Introduction {#sec1}
===============

Irritable bowel syndrome (IBS) is a chronic, recurrent functional gastrointestinal (GI) disorder characterized by altered bowel habits and abdominal pain or discomfort \[[@B1]\]. The prevalence of IBS ranges from 5% to 20% in the general population worldwide \[[@B2]\]. The high prevalence of IBS results in a substantial socioeconomic burden through decreased work productivity and quality of life and increased direct and indirect healthcare costs \[[@B3]--[@B5]\]. The direct and indirect healthcare costs related to IBS in the United States have been steadily increasing and amounted to 1.35 billion dollars in 2003 \[[@B6]\]. The worldwide health costs associated with IBS are estimated to exceed 200 billion dollars \[[@B7]\].

The etiology and pathophysiology of IBS remain less understood. Abnormal intestinal motility, visceral hypersensitivity, abnormal neurohormonal responses to stimuli or stress, and alteration of normal intestinal microflora are related to IBS \[[@B1]\]. The available western medications mainly target symptom relief, such as antispasmodics, fiber supplementation, and antidepressants. Due to limited therapeutic efficacy and the side effects of western medications, up to 51% of IBS patients, especially IBS-D patients, are interested in complementary and alternative medicine (CAM) \[[@B8], [@B9]\]. Moxibustion is a type of CAM approach that stimulates specific points to improve general health and treat chronic conditions with heat generated by burning dried mugwort (*Artemisia vulgaris*) leaves \[[@B10]\].

The average incidence of diarrhea-predominant IBS (IBS-D) is quite high and is showing an increasing trend; it seriously impacts the life quality of patients \[[@B11]\]. In CAM practice, most IBS-D patients have a deficiency of both the spleen and stomach, insufficiency of the kidney yang, and incoordination between the liver and the spleen which are suitable for moxibustion therapy \[[@B12]\]. Although a meta-analysis showed that moxibustion can improve global symptoms of IBS, no systematic study has evaluated the effectiveness of moxibustion treatment for IBS-D \[[@B13]\]. Moreover, some studies including acupuncture or pharmacological medications may influence results \[[@B14], [@B15]\].

Therefore, we conducted a systematic review and meta-analysis to evaluate all the currently available randomized controlled trials (RCTs) of moxibustion compared with pharmacological medications for symptom improvement in IBS-D patients.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We searched the following electronic databases through March 2015: PubMed, Ovid Embase, Web of Science, and Cochrane Library databases, Chinese National Knowledge Infrastructure (CNKI) Database, Wanfang Database, Chinese Biomedical (CBM) Database, Chinese Science and Technology Periodical Database (VIP), and Allied and Complementary Medicine Database (AMED). We used a combination of medical subject headings without language limitation:*irritable bowel syndrome* (IBS),*diarrhea*,*diarrhea-predominant irritable bowel syndrome*,*moxibustion*,*moxibustion therapy*,*moxa-moxibustion*,*warm-moxibustion*,*complementary therapies*,*Chinese medicine*,*traditional medicine*,*alternative medicine*,*complementary medicine*,*randomized controlled trial*, and*controlled clinical trial*. Reference lists from trials selected by electronic searching and conference compilations were manually searched. The literature search was conducted by Bozong Tang and Zongguo Yang independently.

2.2. Study Selection {#sec2.2}
--------------------

Two authors independently selected trials and discussed inconsistencies. Articles that met the following criteria were included: (1) randomized controlled trials; (2) patients with chronic IBS-D; (3) intervention that was moxibustion compared with western medications; (4) studies that measured improvement of symptoms or scores; and (5) available full text. Studies that included other treatments influencing the curative effect of moxibustion, including acupuncture and electroacupuncture, were excluded.

2.3. Data Extraction and Quality Assessment {#sec2.3}
-------------------------------------------

Two reviewers screened all the retrieved trials independently and extracted the following content: publication data, study design, sample size, subject characteristics, treatment protocol, and outcome measurement. The methodological qualities of all the eligible RCTs were assessed independently by two reviewers according to Cochrane Collaboration\'s tool described in Handbook version 5.1.0 \[[@B16]\]. Two authors (Bozong Tang and Zongguo Yang) assessed the quality independently, and inconsistency was discussed with a third review author (Jiang Lin) who acted as an arbiter.

2.4. Statistical Methods {#sec2.4}
------------------------

Data were processed in accordance with the Cochrane Handbook \[[@B16]\]. Intervention effects were presented with odds ratios (ORs) and 95% confidence intervals (CIs) for dichotomous data and mean differences (MDs) and 95% CIs for continuous data. Continuous data of subgroups of each study were pooled using the following formula \[[@B17]\]:$$\begin{matrix}
{SD = \sqrt{\frac{\left( {N_{1} - 1} \right){SD}_{1}^{2} + \left( {N_{2} - 1} \right){SD}_{2}^{2} + \left( {{N_{1}N_{2}}/\left( {N_{1} + N_{2}} \right)} \right)\left( {M_{1}^{2} + M_{2}^{2} - 2M_{1}M_{2}} \right)}{N_{1} + N_{2} - 1}},} \\
\end{matrix}$$where SDs were the standard deviations, *N*s were the sample sizes, and *M*s were the means.

Heterogeneity across studies was informally assessed by visual inspection of forest plots and formally estimated by Cochran\'s *Q* test, which uses a chi-square distribution to make inferences about the null hypothesis of homogeneity (considered significant at *P* \< 0.10). A rough guide to our interpretation of *I* ^2^ was as follows:At 0--40%, it may not be important.At 30--60%, it may represent moderate heterogeneity.At 50--90%, it may represent substantial heterogeneity.At 75--100%, it reflects considerable heterogeneity \[[@B16], [@B18]\].

If the eligibility of any study in the meta-analysis was dubious because of incomplete data, a sensitivity analysis was performed. If there was no heterogeneity among the trials, a fixed effects model would be applied in a meta-analysis. If there was heterogeneity among the trials, a random-effects model would be used instead in the meta-analysis. A description analysis was performed if the quantitative data could not be pooled. Review Manage (RevMan) version 5.3 software was used for data analysis.

3. Results {#sec3}
==========

3.1. Study and Patient Characteristics {#sec3.1}
--------------------------------------

After primarily searching in 7 databases, 165 papers were found. However, 144 papers were excluded due to ineligibility after reviewing the titles and the abstracts. Additional 14 papers were excluded due to duplication and unavailable information on participants, interventions, and outcomes. Finally, 7 randomized controlled trials \[[@B12], [@B19]--[@B24]\] were included in this review: 3 trials published in English journals and 4 trials published in Chinese journals ([Figure 1](#fig1){ref-type="fig"}). A total of 568 patients were randomly treated with moxibustion or a pharmacological medication. The baseline characteristics of patients included in this meta-analysis are described in [Table 1](#tab1){ref-type="table"}.

3.2. Methodological Quality Assessment {#sec3.2}
--------------------------------------

All studies included in this meta-analysis were randomized controlled trials. Four studies \[[@B12], [@B19]--[@B21]\] did not report the method of randomization, whereas the other three reported a randomization number sequence or adaptive minimization randomization scheme \[[@B22]--[@B24]\]. Except for Ma et al.\'s study using the single blind method, all the other studies did not adopt a blind method. These studies had high performance bias and detection bias. Selective reporting was found in Chen and Wang\'s study \[[@B23]\] because it did not present the ITT analysis data. The other potential biases were unclear in these trials ([Figure 2](#fig2){ref-type="fig"}). Because all the studies were conducted in China and clinical outcomes of overall IBS-D symptoms and scores were subjective, we cautiously drew the conclusion that publication bias might have been present in this meta-analysis.

3.3. Overall IBS-D Symptoms or Scores {#sec3.3}
-------------------------------------

The efficacy of moxibustion treatment alone was compared with that of pharmacological medication treatment in 7 studies \[[@B12], [@B19]--[@B24]\]. Improvement of global IBS-D symptoms was reported in 4 studies \[[@B19], [@B20], [@B22], [@B23]\], and improvement of IBS-D scores was reported in the other 3 studies \[[@B20], [@B21], [@B24]\]. There was no significant heterogeneity among the included studies \[[@B19]--[@B24]\] (*P* = 0.97, *I* ^2^ = 0%). A random-effect model was applied to compare the efficacy of moxibustion treatment and medication treatment. The effects of moxibustion on the improvement of the effective rate of overall IBS-D symptoms and the overall IBS-D symptoms scores were both superior to those of medication (*P* = 0.0002, [Figure 3(a)](#fig3){ref-type="fig"}, and *P* = 0.0001, [Figure 3(b)](#fig3){ref-type="fig"}).

3.4. Specific IBS-D Symptoms {#sec3.4}
----------------------------

Improvement of specific IBS-D symptoms such as abdominal pain, abdominal distension, abnormal stool, and defecation frequency was reported in 2 studies \[[@B20], [@B22]\]. The heterogeneity of abdominal pain, abdominal distension, abnormal stool, and defecation frequency among the included studies was not significant before treatment (*P* = 0.69, *P* = 0.94, *P* = 0.78, and *P* = 0.54, resp.). However, the heterogeneity of the specific symptoms, except for defecation frequency, was significant after treatment. Thus, a random-effects model was applied to compare the efficacy of moxibustion treatment and medication treatment. There was no significant difference in improvement of abdominal pain and abnormal stool between the two treatments (*P* = 0.21 and *P* = 0.95, Figures [4(a)](#fig4){ref-type="fig"} and [4(c)](#fig4){ref-type="fig"}). However, the improvement of abdominal distension and defecation frequency with moxibustion treatment was superior to medication treatment (*P* = 0.02 and *P* = 0.02, Figures [4(b)](#fig4){ref-type="fig"} and [4(d)](#fig4){ref-type="fig"}).

3.5. Adverse Events {#sec3.5}
-------------------

Only one trial reported two cases of mild-to-moderate allergy related to moxibustion, which disappeared after stopping the treatment \[[@B24]\]. The other six trials did not report adverse events.

4. Discussion {#sec4}
=============

IBS is a functional gastrointestinal disorder characterized by chronic or recurrent abdominal pain and/or abdominal discomfort associated with abnormal bowel movement \[[@B1]\]. The diagnosis of IBS is currently based on the presence of characteristic symptoms (abdominal pain/discomfort, bloating/distension, and alterations in defecatory function) and in the absence of organic diseases of the gastrointestinal tract \[[@B25], [@B26]\]. According to the symptoms, IBS can be divided into different subtypes. Based on the Rome III diagnostic criteria that is currently widely used, IBS is classified into four subtypes including IBS-D, IBS-C (constipation-predominant), IBS-M (mixed), and IBS-U (unspecified), whereas IBS-D is the most common subtype in China \[[@B1], [@B27], [@B28]\].

The pathophysiology of IBS includes abnormal intestinal motility, visceral hypersensitivity, psychosocial distress, neuromodulation disorder in postinfection, and imbalanced gut microbiota \[[@B29]\]. Antispasmodics, antidiarrheals, 5-hydroxytryptamine 3 (5-HT~3~) receptor antagonist \[[@B30]\], probiotics \[[@B31]\], selective serotonin reuptake inhibitors \[[@B29]\], and antibiotics \[[@B32]\] are used to treat IBS-D. Antispasmodics plus stool consistency modifiers are the first-line options to treat the major symptoms and defecation. However, several systematic reviews conducted by the American College of Gastroenterology Task Force showed poor quality of evidence that particular antispasmodics and antidiarrheals can reduce defecation frequency but that they cannot affect the overall symptoms of IBS; 5-HT~3~ agonists carry a possible risk of ischemic colitis and cardiovascular events \[[@B1]\]. A meta-analysis reported that the response rate to placebo was 42.6%, which was similar to that of conventional pharmacological medication \[[@B33]\]. Therefore, the unsatisfactory therapeutic efficacy and side effects of conventional pharmacological medication are influencing researchers to try to find more effective and safer therapies in CAM.

Moxibustion is not only a treatment approach of CAM but also an important component of traditional Chinese medicine (TCM). There are several types of moxibustion including scarring moxibustion (burning moxa on the skin), warming moxibustion (burning moxa above the skin), and herb-partition moxibustion (indirect burning interposed by various materials). Warming moxibustion is the most practical and convenient approach in clinical practice \[[@B34]\]. According to TCM theory, moxibustion warms the interior and dissipates the cold, regulates qi and resolves stasis, softens and dissolves mass, resuscitates yang, and warms and activates the meridians. Previous studies indicate that moxibustion could relieve chronic visceral hyperalgesia (CVH) by activating the spinal dynorphin and orphanin-FQ system \[[@B34]\], decreasing hypothalamic corticotrophin releasing hormone levels \[[@B35]\], and decreasing prokineticin-1 and prokineticin receptor-1 expression \[[@B36]\]. Moxibustion also could enhance the pain threshold and restore sensitivity by decreasing 5-hydroxytryptamine concentration in the colon tissue \[[@B37]\]. A clinical study observed the change in colonic mucosal 5-HT~3~ among IBS-D patients and assessed the efficacy of herb-partitioned moxibustion. The results showed that IBS-D patients had a significantly increased expression of 5-HT~3~ in the colonic mucosa, whereas herb-partitioned moxibustion simultaneously improved IBS-D symptoms and downregulated the level of 5-HT~3~ \[[@B37]\].

Our meta-analysis showed that moxibustion could improve global IBS-D patient symptoms and scores, which was consistent with previous studies \[[@B39], [@B40]\]. In our meta-analysis, Jin and Chu et al. \[[@B20], [@B22]\] reported that moxibustion could relieve diarrhea and abdominal pain in IBS-D patients, which was in accordance with the results of Liu and Wu et al. \[[@B37], [@B38]\]. However, the improvement of abdominal pain and abnormal stool was not significantly different in our meta-analysis with moxibustion treatment, whereas abdominal distension and defecation frequency improved significantly. These findings might be associated with different frequencies of intervention, duration of study, patient age, duration of run-in period, male-to-female ratio, the number of patients in the treatment group or control group, or the number of doctor visits.

Systematic reviews and meta-analyses are often limited by the quality of the included studies. First, the sample size is small, in which only 568 patients were included in both moxibustion and pharmacological medication groups. Second, the treatment mode and the duration were not equivalent; thus, we could not confirm how long moxibustion treatment is required to achieve a benefit when treating IBS-D. Third, because the assessment of improved symptoms of IBS-D was not the same, it was difficult to accurately assess the effect of moxibustion. Fourth, because only one study reported the side effects of moxibustion, we could not assess the overall side effects during treatment of IBS-D. Fifth, the quality of the present evidence is limited considering that most of the included studies were given a high risk of performance bias for key methodological elements of adequate random sequence generation and allocation concealment. Finally, no studies reported an improvement in quality of life for IBS-D patients, which is correlated with the appearance of symptoms, protracted time, and severity of the disease \[[@B41], [@B42]\].

This meta-analysis showed that moxibustion might be beneficial for IBS-D patients. However, this review had some limitations. The data are insufficient to recommend the method as a first-line treatment or to establish the quality of life and long-term results. Therefore, further research is required to more accurately assess the results of moxibustion for treating IBS-D.

This work was supported, in part, by the National Natural Science Foundation of China (81173222) and research subject in hospital (201509).

Disclosure
==========

The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.

Competing Interests
===================

The authors declare that they have no competing interests.

Authors\' Contributions
=======================

Bozong Tang and Jianliang Zhang contributed equally to this work.

![Flow diagram of the study selection process.](ECAM2016-5105108.001){#fig1}

![Risk of bias assessment.](ECAM2016-5105108.002){#fig2}

![Improvement of overall IBS-D symptoms and scores.](ECAM2016-5105108.003){#fig3}

![Improvement of specific IBS-D symptoms.](ECAM2016-5105108.004){#fig4}

###### 

Baseline characteristics of included randomized controlled trials for IBS-D.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\            Number of patients   Publishing language   Diagnostic criteria                                                                  Criteria for improvement in overall IBS-D symptoms   Time point for outcome assessment     Moxibustion treatment(s)                                     Control treatment(s)
  year                                                                                                                                                                                                                                                                                                      
  ----------------- -------------------- --------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------- ------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------
  Ni and Lu \       56                   English               Negative GI investigations and standards for clinical diagnosis for IBS from 1986\   Change of total IBS symptom score (predefined)       15 days (EoT)                         Fixed points                                                 Nifedipinum, 10 mg t.i.d.
  2001 \[[@B12]\]                                              National conference for chronic diarrhea                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                            

  Zhang et al.  \   60                   Chinese               Rome II                                                                              ≥30% improvement in global IBS symptoms              2 weeks (EoT)                         Ginger-partitioned and fixed points                          Diet, psychiatric, and antidiarrheal therapy Enterosoluble glutamine 0.4 g t.i.d. or Smecta 3 g t.i.d. or probiotics 630 mg t.i.d.
  2007 \[[@B19]\]                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                            

  Jin\              78                   Chinese               Rome II                                                                              ≥30% improvement in global IBS symptoms              30 days (EoT)                         Traditional Chinese ointments-partitioned and fixed points   Berberine hydrochloride 2 tablets t.i.d.
  2009 \[[@B20]\]                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                            

  Sheng et al.  \   40                   English               Rome III                                                                             ≥30% improvement in global IBS symptoms              4 weeks (EoT and 1-month follow-up)   Herbal cone-partitioned and fixed points                     Pinaverium bromide 50 mg t.i.d.
  2011 \[[@B21]\]                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                            

  Chu et al.  \     60                   Chinese               Rome II and TCM criteria                                                             ≥30% improvement in global IBS symptoms              15 days (EoT)                         Syndrome differentiation and treatment                       Loperamide 2 mg b.i.d.
  2011 \[[@B22]\]                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                            

  Chen and Wang \   64                   Chinese               Rome III                                                                             ≥50% improvement in global IBS symptoms              30 days (EoT)                         Fixed points                                                 Trimebutine maleate tablets 100 mg t.i.d.
  2013 \[[@B23]\]                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                            

  Ma et al.  \      210                  English               Rome III                                                                             GSRS total score                                     4 weeks (EoT)                         Medicamental pulverata-partitioned and fixed points          Pinaverium bromide 50 mg t.i.d.
  2013 \[[@B24]\]                                                                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IBS-D: diarrhea-predominant IBS; t.i.d.: three times a day; GSRS: gastrointestinal symptom rating scale; EoT: end of treatment; TCM: traditional Chinese medicine.
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